Montelukast inhibits neutrophil pro-inflammatory activity by a cyclic AMP-dependent mechanism

British Journal of Pharmacology

Volumn 156, Issue 1, 2009, Pages 105-115

  Anderson, Ronald ^a,b,c   Theron, Annette J ^b,c   Gravett, Cornelia M ^b,c   Steel, Helen C ^b,c   Tintinger, Gregory R ^b,c   Feldman, Charles ^d  

^a Department of Immunology ^*  (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Adenosine 3 ,5 cyclic monophosphate; Calcium; Elastase; Leukotriene B 4; Montelukast; Neutrophils; Phosphodiesterases; Reactive oxygen species

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ADENOSINE TRIPHOSPHATE; CYCLIC AMP; ELASTASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; ISOBUTYLMETHYLXANTHINE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PHOSPHODIESTERASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROLIPRAM; SALBUTAMOL; THROMBOCYTE ACTIVATING FACTOR; ACETIC ACID DERIVATIVE; CALCIUM; CHEMOTACTIC FACTOR; CYCLIC AMP PHOSPHODIESTERASE; FLUORESCENT DYE; FURA 2; LEUKOTRIENE D4 RECEPTOR; LEUKOTRIENE RECEPTOR; PANCREATIC ELASTASE; QUINOLINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CALCIUM TRANSPORT; CHEMOLUMINESCENCE; COLORIMETRY; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; HUMAN; HUMAN CELL; IC 50; INFLAMMATION; NEUTROPHIL; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RADIOMETRY; SPECTROFLUOROMETRY; STATISTICAL ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; IN VITRO STUDY; LEUKOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ACETATES; CALCIUM; CHEMOTACTIC FACTORS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT DYES; FURA-2; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE B4; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHIL ACTIVATION; NEUTROPHILS; PANCREATIC ELASTASE; QUINOLINES; REACTIVE OXYGEN SPECIES; RECEPTORS, LEUKOTRIENE;

EID: 65549132863     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2008.00012.x     Document Type: Article

References (49)

1. Ali H, Sozzani S, Fisher I, Barr AJ, Richardson RM, Haribabu B et al. (1998). Differential regulation of formyl peptide and platelet-activating factor receptors: role of phospholipase Cβ3 phosphorylation by protein kinase A. J Biol Chem 273 : 11012 11016.
2. Anderson R, Goolam Mahomed A, Theron AJ, Ramafi G, Feldman C (1998). Effects of rolipram and dibutyryl cyclic AMP on resequestration of cyto/ic calcium in FMLP-activated human neutrophils. Br J Pharmacol 124 : 547 555.
3. Anderson R, Visser SS, Ramafi G, Theron AJ (2000). Accelerated resequestration of cyto/ic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680. Br J Pharmacol 130 : 717 724.
4. Anonymous (2004). Drug Review. Asthma. Montelukast, drugs in context. Part E. Respir Med Infect 1 : 1 40.
5. 3 receptor. Respir Res 7 : 34.
6. Barnes PJ (2007). New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol 119 : 1055 1062.
7. Beatty K, Robertie P, Senior RM, Travis J (1982). Determination of oxidized alpha-1-proteinase inhibitor in serum. J Lab Clin Med 100 : 186 192.
8. Bengis-Garber C, Gruener N (1996). Protein kinase A downregulates the phosphorylation of p47 phox in human neutrophils: a possible pathway for inhibition of the respiratory burst. Cell Signal 8 : 291 296.
9. 2+ influx in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 290 : L278 L283.
10. Bréchard S, Tschirhart EJ (2008). Regulation of superoxide production in neutrophils: role of calcium influx. J Leuk Biol 84 : 1 15.
11. Burelout C, Thibault N, Harbour D, Naccache PH, Bourgoin SG (2007). The PGE2-induced inhibition of the PLD activation pathway stimulated by fMLP in human neutrophils is mediated by PKA at the PI3-Kgamma level. Biochem Pharmacol 74 : 730 741.
12. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorganioglu A (2005). Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 99 : 444 450.
13. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N et al. (1996). Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 13 : 445 448.
14. Currie GP, Srivastava P, Dempsey OJ, Lee DKC (2005). Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. Q J Med 98 : 171 182.
15. Diamant Z, van der Molen T (2005). Treating asthma: is there a place for leukotriene receptor antagonists? Respir Med 99 : 655 662.
16. 1 receptor antagonist with broad anti-inflammatory activity. Eur J Pharmacol 504 : 223 233.
17. Fitzgerald DA, Mellis CM (2006). Leukotriene receptor antagonists in virus-induced wheezing: evidence to date. Treat Respir Med 5 : 407 417.
18. Flamand N, Surette ME, Picard S, Bourgoin S, Borgeat P (2002). Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 62 : 250 256.
19. Fleisch JH, Rinkema LE, Marshall WS (1984). Pharmacologic receptors for the leukotrienes. Biochem Pharmacol 33 : 3919 3922.
20. Fox-Spencer R (2006). Drug review. Allergic rhinitis and asthma. Montelukast. Drugs Context 2 : 413 456.
21. Geiszt M, Kapus A, Nemet K, Farkas L, Ligeti F (1997). Regulation of capacitative calcium influx in neutrophil granulocytes: alterations in chronic granulomatous disease. J Biol Chem 272 : 26471 26478.
22. 2+ indicators with greatly improved fluorescent properties. J Biol Chem 260 : 3440 3450.
23. Hay DWP, Muccitelli RM, Tucker SS, Vickery-Clark LM, Wilson KA, Gleason JG et al. (1987). Pharmacologic profile of SK&F 104353: a novel potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther 243 : 474 481.
24. Henderson WR Jr., Chiang GK, Tien YT, Chi EY (2006). Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am J Respir Crit Care Med 173 : 718 728.
25. Holmsen H, Storm E, Day HJ (1972). Determination of ATP and ADP in blood platelets: a modification of the firefly luciferase assay for plasma. Anal Biochem 46 : 489 501.
26. Iannone MA, Wolberg G, Zimmerman TP (1989). Chemotactic peptide induces cAMP elevation in human neutrophils by amplification of the adenylate cyclase response to endogenously produced adenosine. J Biol Chem 264 : 20177 20180.
27. Jones TR, Labelle M, Belley M, Champion E, Charette L, Ford-Hutchinson AW et al. (1995). Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can J Physiol Pharmacol 73 : 191 201.
28. Knorr B, Holland S, Schwartz J, Douglas Rogers J, Reiss TF (2001). Clinical pharmacology of montelukast. Clin Exp Allergy Rev 1 : 254 260.
29. 4, C4 and D4 in human polymorphonuclear leukocytes. Blood 93 : 1399 1405.
30. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I et al. (1999). Montelukast added to inhaled beclamethasone in treatment of asthma. Am J Respir Crit Care Med 160 : 1862 1868.
31. Mamedova L, Capra V, Accomazzo MR, Gao ZG, Ferrario S, Fumagalli M et al. (2005). CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors. Biochem Pharmaol 71 : 115 125.
32. Minkenberg I, Ferber E (1984). Lucigenin-dependent chemiluminescence as a new assay for NADPH-oxidase activity in particulate fractions of human polymorphonuclear leukocytes. J Immunol Methods 71 : 61 67.
33. Mundell SJ, Olah ME, Panettieri RA, Benovic JL, Penn RB (2001). Regulation of G-protein-coupled receptor-adenyl cyclase responsiveness in human airway smooth muscle by exogenous and autocrine adenosine. Am J Respir Cell Mol Biol 24 : 155 163.
34. Muz MH, Deveci F, Bulut Y, Illhan N, Yekeler H, Turgut T (2006). The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. Exp Mol Med 38 : 109 118.
35. Nayak A, Langdon RB (2007). Montelukast in the treatment of allergic rhinitis. An evidence-based review. Drugs 67 : 887 901.
36. Nick JA, Avdi NJ, Young SK, Knall C, Gerwins P, Johnson GL et al. (1997). Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP. J Clin Invest 99 : 975 986.
37. Peters-Golden M, Henderson WR (2007). Leukotrienes. N Engl J Med 357 : 1841 1854.
38. Ramires R, Caiaffa ME, Tursi A, Haeggström JZ, Macchia L (2004). Novel inhibitory effects on 5-lipoxygenase activity by the anti-asthma drug montelukast. Biochem Biophys Res Commun 324 : 815 821.
39. Riccioni G, Bucciarelli T, Mancini B, Di Ilio C, D'Orazio N (2007). Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem 14 : 1966 1977.
40. Rubinstein I, Kumar B, Schriever C (2004). Long-term montelukast therapy in moderate to severe COPD- a preliminary observation. Respir Med 98 : 134 138.
41. 2+ channels by cyclic nucleotide cross activation of opposing protein kinases in rabbit portal vein. Circ Res 82 : 557 565.
42. Steel HC, Anderson R (2002). Dissociation of the PAF-receptor from NADPH oxidase and adenylate cyclase in human neutrophils results in accelerated influx and delayed clearance of cyto/ic calcium. Br J Pharmacol 136 : 81 89.
43. 4. Clin Exp Immunol 150 : 144 150.
44. Tintinger GR, Theron AJ, Steel HC, Anderson R (2001). Accelerated calcium influx and hyperactivation of neutrophils in chronic granulomatous disease. Clin Exp Immunol 123 : 254 263.
45. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttman MA, Hay DW et al. (1994). Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophils influx in guinea pigs. J Pharmacol Exp Ther 270 : 250 259.
46. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM (1999). Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56 : 170 174.
47. Wu Y, Zhou C, Tao J, Li S (2006). Montelukast prevents the decrease of interleukin-10 and inhibits NF-kappa B activation in inflammatory airway of asthmatic guinea pigs. Can J Physiol Pharmacol 84 : 531 537.
48. Yang Y, Luo J, Kazumura K, Takeuchi K, Inui N, Hayashi H et al. (2006). Cilostazol suppresses adhesion of human neutrophils to HUVECs stimulated by FMLP and its mechanisms. Life Sci 79 : 629 636.
49. Zhu J, Qiu YS, Figueroa DJ, Bandi V, Galczenski H, Hamada K et al. (2005). Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 33 : 531 540.